Evaxion Biotech, a clinical-stage TechBio company specialising in developing AI-Immunology powered vaccines, presented its AI model designed to predict patient responses to cancer immunotherapy at the Biomarkers & Precision Oncology Europe conference in Berlin, Germany.
The broad use of immunotherapy drugs called checkpoint inhibitors has significantly advanced cancer treatment.
However, their effectiveness is limited, with success rates at approximately 15% for most cancers.
This inherent challenge emphasises the critical need for a reliable approach to identify the patients who will benefit from standard-of-care cancer immunotherapy. This can improve patient outcomes and reduce healthcare costs.
"Building upon Evaxion’s core competencies, we have developed an AI model that shows promising results in predicting patients at risk of advancing into progressive disease while undergoing checkpoint inhibitor therapy, enabling earlier intervention with alternative treatments,” commented Christian Kanstrup, Evaxion’s Chief Executive Officer.
Christian continued: “We set out to improve patient outcomes and address the growing healthcare burden by developing our first checkpoint inhibitor response predictor model."
"The model relies on our unique AI-Immunology platform, builds upon our existing core competencies and is part of the “Responder” leg of our corporate strategy."
"This presentation marks our first step on our journey towards this goal, and we will develop a commercial offering wherein collaboration and partnerships will be instrumental to achieving our vision for a more cost-effective and efficient healthcare system ... as well as improving patient outcomes.”
